Welcome On Board Dr. Fritzinger

It is our pleasure to announce that Dr. David Fritzinger joins Covalent's team and brings 30+ years of expertise in Molecular Biology plus his experience as Executive at different Life Sciences and Drug Development Companies. Dr. Fritzinger is a seasoned molecular biologist and protein chemist with over 10 years experience working on the early-stage development of protein therapeutics. He received his BS in Chemistry from Purdue University and his Ph.D. from the University of Massachusetts at Amherst, where he studied conformational changes in tRNA caused by changes in solution conditions or minoacylation. Dr. Fritzinger performed his post-doctoral research at the University of Bristol, working in the lab of Nigel Brown. Following his post-doc, Dr. Fritzinger held several positions in academia and at biotechnology companies. His last position was as an Associate Professor at the University of Hawaii Cancer Center, where he performed structure/function studies on human complement C3. While at the UH Cancer Center, Dr. Fritzinger was the co-founder of a startup biotech company, InCode Biopharmaceutics, Inc., that was based on the Intellectual Property from his laboratory. Dr. Fritzinger was the Chief Scientific Officer at InCode, where he directed all discovery research for the company and managed the work of both CROs and CMOs in producing large quantities of the company’s lead protein, both in insect and mammalian cells. Previous to his work at UH and InCode, Dr. Fritzinger was the director of the DNA sequencing and genotyping core at Myriad Genetics, Inc. Dr. Fritzinger has started a consulting company, Fritzinger Biopharma Consulting, LLC, where he provides consulting services in molecular biology, protein chemistry, and biologics development. He is currently working on a early-stage development project on a biologic that may be applicable to a number of indications.